RE: Hemo Article about time15 Apr 2024 16:09
2nd part of article, great to see something positive
work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the 'father' of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university's involvement, Sandler said: 'This isn't a situation where we've paid [UPenn] to carry out the work. They don't work like that. All along it been data driven.'
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above.
If all of this suggests that Hemogenyx is a one-trick pony, then that would be misleading.
Before moving into the area of CAR-T, its team together with Eli Lilly, developed a breakthrough that enhances bone marrow and stem cell transplant procedures
The approach focuses on the initial critical stages of eradicating diseased cells and replacing them with healthy ones, using a CDX bi-specific antibody that is both safer and more effective than traditional chemotherapy.
'We decided to do something that other people wouldn't touch at that time,' says Sandler. This has been a theme with all of Hemogenyx's research - attempting the difficult.
As such, the company has created and is a leader in the field of chimeric bait receptors. Put simply, CBRs are designed to attract and catch harmful cells, like cancer cells, by pretending to be something the harmful cells want to attach to.
Once the bad cells latch onto these bait receptors, the immune system can easily find and destroy them.
Its research is being deployed to combat brain cancers such as glioblastoma and neurodegenerative diseases where delivering therapeutics across the blood-brain barrier has long been problematic.
At the same time, it is working on intranasal delivery of CBRs to tackle airborne viral infections, an area of research germane to the civil defence industry and the military.
While Sandler wouldn't be drawn on exactly who he is talking to, there are discussions with parties interested in helping develop the viral infections defense deployment, the CEO confirmed.
'We are talking to institutions and agencies,' Sandler says. 'There is a lot of interest and we are moving these conversations along.
The Ice Age-like big freeze across the small-cap market in the UK means none of company's potential has been captured in the current share price, which values Hemogenyx at a bargain basement £21million
Sign In
Follow the stocks
